Pharma News - Chemdiv

New approach increases the likelihood of detecting antiphospholipid syndrome

The Geneva University Hospitals (HUG), the University of Geneva (UNIGE) and their spin-off Endotelix have created the best possible target molecule for the antibodies responsible for antiphospholi...

Researchers unravel how the brain chemical dopamine relates to schizophrenia

Researchers at the Lieber Institute for Brain Development (LIBD) believe they have solved a riddle that has challenged scientists for more than 70 years: how the brain chemical dopamine relates to ...

Cellular Biomedicine Lung Cancer IND Application Approved

The FDA has approved Cellular Biomedicine’s Investigational New Drug (IND) application for its tumor infiltrating lymphocyte (TIL) drug candidate C-TIL051 for late-stage non-small cell lung cance...

Ancient viral DNA in human genome guards against infections

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new research. ...

C-reactive Protein Score May Predict PD-1 Inhibitor Treatment Efficacy in Intrahepatic Cholangiocarcinoma

The C-reactive protein (CRP) score may be the most effective inflammation-based score to predict the overall survival (OS) of patients with intrahepatic cholangiocarcinoma (ICC) treated with anti-p...

Researcher combines AI and microelectronics to create neural implants that fight brain disorders

Neural implants can help treat brain disorders such as Parkinson's disease and epilepsy by directly modulating abnormal activities — and the University of Toronto's Xilin Liu is working with mic...

$MT-101 Granted Fast Track Designation by FDA for CD5+ Relapsed/Refractory Peripheral T-Cell Lymphoma$

MT-101 Granted Fast Track Designation by FDA for CD5+ Relapsed/Refractory Peripheral T-Cell Lymphoma

Patients with CD5-positive relapsed/refractory peripheral T-cell lymphoma may derive benefit from MT-101, which was granted fast track designation by the FDA.

ITM Gets Fast Track for Radiopharmaceutical Treatment for Neuroendocrine Tumors

ITM Isotope Technologies Munich has received FDA’s Fast Track designation for ITM-11, an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors. ...

Exploring novel mechanisms and therapeutic targets for acute myeloid leukemia

Patients with acute myeloid leukemia, the most common type of adult blood cancer, show large-scale genomic mutations and altered DNA folding patterns that could help identify potential therapeutic ...

Diet drug jab could help patients lose 10% of their weight in months by taking over body's appetite-regulating system, scientists say

An injection can help the overweight lose nearly a tenth of their body weight in just a few months, claim scientists. Researchers say the drug – yet to be named – hijacks a patient's appetite-r...

Cladribine Shows Efficacy, Tolerability Among Patients With MS Switching From Infusion DMTs

In a small real-world cohort, annualized relapse rates were reduced for patients with multiple sclerosis who switched to cladribine (Mavenclad; EMD Serono) from ocrelizumab (Ocrevus; Genentech), na...

Stevanato and DWK Life Sciences Enter Non-Exclusive Agreement

Stevanato Group S.p.A., a global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, and DWK Life Sciences, a global manufacturer...